Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE versus NESACAINE MPF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE versus NESACAINE MPF.
LIDOCAINE vs NESACAINE-MPF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a sodium channel blocker that inhibits the influx of sodium ions into cardiac Purkinje fibers and myocytes, thereby stabilizing the neuronal membrane and decreasing automaticity. It also exhibits local anesthetic effects by reversibly binding to voltage-gated sodium channels in nerve cell membranes, blocking impulse conduction.
Nesacaine-MPF (chloroprocaine) is an ester-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking impulse conduction in nerve fibers.
For ventricular arrhythmias: IV bolus 1-1.5 mg/kg, then continuous infusion 1-4 mg/min. For local anesthesia: 0.5-2% solution, max 4.5 mg/kg (300 mg) without epinephrine, 7 mg/kg (500 mg) with epinephrine.
1% solution: 2.5-30 mL (25-300 mg) subcutaneously or locally; maximum 30 mL per dose. 2% solution: 1.25-15 mL (25-300 mg) subcutaneously or locally; maximum 15 mL per dose.
None Documented
None Documented
Clinical Note
moderateLidocaine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lidocaine is combined with Fluticasone propionate."
Clinical Note
moderateLidocaine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Lidocaine."
Clinical Note
moderateLidocaine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Lidocaine."
Clinical Note
moderateLidocaine + Erythromycin
Terminal elimination half-life 1.5-2 hours (normal hepatic function). In CHF or hepatic impairment, prolonged to 6-8 hours; in neonates, 3-6 hours. Context: rapid redistribution after IV bolus (alpha half-life ~8 min) accounts for brief clinical effect, while terminal half-life determines accumulation with infusion.
Terminal half-life: 3-4 hours (adults); prolonged in hepatic or renal impairment.
Renal excretion of metabolites: 4-hydroxyxylidine (70-80% renal, 10-20% biliary/fecal), unchanged lidocaine <10% renal. Total renal elimination ~90% (as metabolites), biliary/fecal ~10%.
Renal excretion of metabolites; <10% unchanged drug. Biliary/fecal elimination minor.
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic
"The metabolism of Erythromycin can be decreased when combined with Lidocaine."